5 Key Takeaways
-
1
Higher-volume intravitreal therapies do not significantly elevate intraocular pressure or glaucoma risk in treatment-naïve patients.
-
2
The study analyzed data from over 3,700 eyes using electronic health records from Vestrum Health.
-
3
Mean intraocular pressure remained stable across all treatment groups, with differences within 1 mmHg of baseline.
-
4
No statistically significant increase in glaucoma incidence was observed among patients receiving higher-volume agents.
-
5
Real-world data corroborate clinical trial findings, indicating no increased glaucoma risk with higher-volume injections.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.